Literature DB >> 18281021

HIF-1-regulated vasoactive systems are differentially involved in acute hypoxic stress responses of the developing brain of newborn mice and are not affected by levetiracetam.

Regina Trollmann1, Julia Schneider, Stephan Keller, Katja Strasser, Dieter Wenzel, Wolfgang Rascher, Omolara O Ogunshola, Max Gassmann.   

Abstract

Hypoxia-inducible transcription factor-1 (HIF-1) is critically involved in adaptive endogenous mechanisms to hypoxic brain injury by transcriptional activation of specific target genes that restore oxygen supply. Exogenously, neuroprotective properties of levetiracetam (LEV) have been suggested in experimental cerebral ischemia and epilepsy. We aimed to elucidate 1) effects of acute hypoxic distress on HIF-1 and vasoactive target genes, and 2) effects of LEV on HIF-1-regulated mechanisms in the brain at early developmental stages. To this end, we studied the impact of hypoxia in the presence or absence of LEV on the O2-dependent HIF-1alpha subunit as well as on VEGF and iNOS in the developing brain of normoxic and hypoxic mice. C57BL/6 mice (P0, P7) were treated with saline or LEV (i.p.; 50 mg/kg) 1 h before exposure to either normoxia (21% O2; N) or hypoxia (8% O2 of 6 h; H) without reoxygenation. HIF-1alpha was analyzed by Western blot and immunohistochemistry and mRNA levels were quantified by TaqMan RT-PCR. Hypoxia led to prominent accumulation of cerebral HIF-1alpha protein in cortical neurons and glial cells and significant up-regulation of VEGF mRNA at P0 (N, 0.018+/-0.002, vs. H, 0.031+/-0.003, n=6; p<0.05) and P7 (N, 0.096+/-0.032, vs. H, 0.873+/-0.069, n=7; p<0.001). Interestingly, we detected a significant decrease of iNOS mRNA levels in hypoxic brains. LEV treatment did not alter HIF-1alpha accumulation either in normoxic or hypoxic brains (P0, P7). Moreover, significant changes of VEGF and NOS mRNA levels did not occur with the exception that hypoxia-induced decreased iNOS levels were not observed in P0 brains. We conclude that acute systemic hypoxia differentially affects expression of HIF-1-regulated vasoactive factors in the newborn mouse brain. Of clinical importance, LEV treatment did not alter crucial HIF-1-regulated neuroprotective mechanisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281021     DOI: 10.1016/j.brainres.2007.12.069

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Prodeath or prosurvival: two facets of hypoxia inducible factor-1 in perinatal brain injury.

Authors:  Wanqiu Chen; Robert P Ostrowski; Andre Obenaus; John H Zhang
Journal:  Exp Neurol       Date:  2008-11-11       Impact factor: 5.330

2.  Impaired cerebral angiogenesis in the fetal lamb model of persistent pulmonary hypertension.

Authors:  Susan S Cohen; Bethany R Powers; Alexandra Lerch-Gaggl; Ru-Jeng Teng; Girija Ganesh Konduri
Journal:  Int J Dev Neurosci       Date:  2014-08-27       Impact factor: 2.457

3.  Intravenous Levetiracetam for Treatment of Seizures in Term and Preterm Neonates.

Authors:  Pakize Karaoğlu; Semra Hız; Burçin İşcan; Ayşe I Polat; Müge Ayanoğlu; Nuray Duman; Uluç Yiş'
Journal:  J Pediatr Neurosci       Date:  2020-03-19

4.  Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial.

Authors:  Geraldine Favrais; Moreno Ursino; Catherine Mouchel; Estelle Boivin; Vincent Jullien; Sarah Zohar; Elie Saliba
Journal:  BMJ Open       Date:  2019-01-24       Impact factor: 2.692

5.  Neonatal seizures therapy: we are still looking for the efficacious drug.

Authors:  Carlotta Spagnoli; Elena Pavlidis; Francesco Pisani
Journal:  Ital J Pediatr       Date:  2013-06-05       Impact factor: 2.638

6.  Efficacy of levetiracetam for neonatal seizures in preterm infants.

Authors:  Ji Yoon Han; Chung Joon Moon; Young Ah Youn; In Kyung Sung; In Goo Lee
Journal:  BMC Pediatr       Date:  2018-04-10       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.